
    
      laboratory-confirmed patients using qRT-PCR will be enrolled in the study. Eligibility
      criteria for recipients are ; laboratory-confirmed SARS-CoV-2, Severe or immediately
      life-threatening. Severe disease defined as one or more of the following; shortness of
      breath( dyspnoea), respiratory frequency≥ 30/min, blood oxygen saturation ≤93%, a partial
      pressure of arterial oxygen to fraction of inspired oxygen ratio <300, and lung infiltrates
      >50% within 24-48 hours. While a life-threatening disease is defined as one or more of the
      following; respiratory failure, need for mechanical ventilation, septic shock and multiple
      organ dysfunction or failure.

      Intervention: All patients included in the study provided will be administered with two
      plasma units (each unit is 200cc).

      Primary measure is the degree of clinical improvement among the COVID-19 patients who receive
      CPT within seven days as compared with the patients who receive after seven days. Case
      Fatality will be assessed among the enrolled cases
    
  